Clinical Trial

Alzheimer's Tau Platform: Regimen A - AADvac1

Study acronym: ATP
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-07-10
notable Enrollment increased: 375 -> 450 participants 2026-04-07
Trial Details
NCT Number NCT07167966
Lead Sponsor Paul S. Aisen
Collaborators: Axon Neuroscience SE, University of California, San Francisco, Massachusetts General Hospital, Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, National Institute on Aging (NIA)
Conditions Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
Enrollment 450 participants
Start Date 2026-11-03
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-09